@article{10.37349/etat.2022.00078,
abstract = {The majority of breast cancers express the estrogen receptor (ER) and for this group of patients, endocrine therapy is the cornerstone of systemic treatment. However, drug resistance is common and a focus for breast cancer preclinical and clinical research. Over the past 2 decades, the PI3K/Akt/mTOR axis has emerged as an important driver of treatment failure, and inhibitors of mTOR and PI3K are now licensed for the treatment of women with advanced ER-positive breast cancer who have relapsed on first-line hormonal therapy. This review presents the preclinical and clinical data that led to this new treatment paradigm and discusses future directions.},
author = {Skolariki, Aglaia and D'Costa, Jamie and Little, Martin and Lord, Simon},
doi = {10.37349/etat.2022.00078},
journal = {Exploration of Targeted Anti-tumor Therapy},
pages = {172--199},
title = {{Role of PI3K/Akt/mTOR pathway in mediating endocrine resistance: concept to clinic}},
url = {https://www.explorationpub.com/Journals/etat/Article/100278},
volume = {3},
year = {2022},
number = {2}
}